Prognostic impact of triple negative phenotype in conservatively treated breast cancer

Breast Journal

Volumn 17, Issue 4, 2011, Pages 377-382

  Barbieri, Viviana ^a   Sanpaolo, Pietro ^a   Genovesi, Domenico ^b  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

breast cancer; radiotherapy; triple negative phenotype

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GONADORELIN DERIVATIVE; LETROZOLE; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 79960422923     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2011.01100.x     Document Type: Article

References (29)

1. Sorlie T,. Molecular portraits of breast cancer: tumor subtypes as a distinctive disease entities. Eur J Cancer 2004; 40: 2667-75. (Pubitemid 39574720)
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747-52.
3. Rouzier R, Perou CM, Symmons WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-85. (Pubitemid 41170290)
4. Soutiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-8. (Pubitemid 37071889)
5. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005; 23: 7350-60. (Pubitemid 46202348)
6. Romand EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N Eng J Med 2005; 353: 1673-84. (Pubitemid 41464706)
7. ICRU. Report 62: Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). Bethesda: International Commission on Radiation Units and Measurements, 1999.
8. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-7. (Pubitemid 46631305)
9. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns od recurrence. Clin Cancer Res 2007; 13: 4429-34. (Pubitemid 47219710)
10. Kurtz JM, Jacquemier J, Amelric L, et al. Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancer treated by conservation therapy. Cancer 1990; 65: 1867-78. (Pubitemid 20116664)
11. Leborgne F, Leborgne J, Ortega B, et al. Breast conservation treatment of early stage breast cancer: patterns of failure. Int J Radiat Oncol Biol Phys 1995; 31: 765-75.
12. Dalberg K, Mattson A, Rutqvist LE, et al. Breast conserving surgery for invasive breast cancer: risk factors for ipsilateral breast tumor recurrences. Breast Cancer Res Treat 1997; 43: 73-86. (Pubitemid 27090869)
13. Recht A, Connolly JL, Schmitt SJ, et al. The effect of young age on tumor recurrence in the treated breast after conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1988; 14: 3-10. (Pubitemid 18059122)
14. Fowble BL, Schultz DJ, Overmayer B, et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994; 30: 23-33. (Pubitemid 24291110)
15. de la Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993; 341: 1039-42.
16. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiotherapy. N Engl J Med 2001; 345: 1378-87.
17. Mirza NQ, Vlastos G, Meric F, et al. Predictors of locoregional recurrence among patients with early-stage breast cancer trated with breast-conserving therapy. Ann Surg Oncol 2002; 9: 256-65. (Pubitemid 34298630)
18. Fisher B, Redmond C, Dimitrov NV, et al. A randomised clinical trial evaluating sequential methotrexate and fluoruracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Eng J Med 1989; 320: 473-8. (Pubitemid 19062521)
19. Broet P, de la Rochfordie A, Scholl SM, et al. Analyzing prognostic factors in breast cancer using a multistate model. Breast Cancer Res Treat 1999; 54: 83-9. (Pubitemid 29209921)
20. Swenson KK, Decher L, Haselow R, et al. Prognostic factors after conservative surgery and radiation therapy for early stage breast cancer. Am J Clin Oncol 1998; 21: 111-16. (Pubitemid 28193149)
21. McCready DR, Hanna W, Kahn H, et al. Factors associated with local breast cancer recurrence after lumpectomy alone. Ann Surg Oncol 1996; 3: 358-66. (Pubitemid 126729518)
22. Toboul E, Buffat L, Belkacemi Y, et al. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 1999; 43: 25-38. (Pubitemid 29068606)
23. Veronesi U, Marubini E, Del Vecchio M, et al. Local recurrences and metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995; 87: 19-27.
24. CÃfaro GA, Genovesi D, Marchese R, et al. Predictors of local recurrence after conservative surgery and whole-breast irradiation. Breast Cancer Res Treat 2006; 98: 329-35. (Pubitemid 44195603)
25. Matos I, Dufloth R, Alvarenga M, et al. P63, cytokeratin 5 and p-cadherin: three molecular marker to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005; 447: 688-94. (Pubitemid 41571183)
26. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502. (Pubitemid 43854964)
27. Jacquemier J, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006; 25: 2273-84.
28. Jacquemier J, Padovani L, Rabayrol L, et al. Tipically medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005; 207: 260-8. (Pubitemid 41556449)
29. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423. (Pubitemid 36842560)